Comparative Pharmacology
Head-to-head clinical analysis: MAGNESIUM SULFATE IN DEXTROSE 5 IN PLASTIC CONTAINER versus POTASSIUM CHLORIDE 0 11 IN DEXTROSE 10 AND SODIUM CHLORIDE 0 45 IN PLASTIC CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MAGNESIUM SULFATE IN DEXTROSE 5 IN PLASTIC CONTAINER versus POTASSIUM CHLORIDE 0 11 IN DEXTROSE 10 AND SODIUM CHLORIDE 0 45 IN PLASTIC CONTAINER.
MAGNESIUM SULFATE IN DEXTROSE 5% IN PLASTIC CONTAINER vs POTASSIUM CHLORIDE 0.11% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Magnesium sulfate provides magnesium ions, which are essential for various physiological processes. It acts as a cofactor for enzymatic reactions, stabilizes excitable membranes, and antagonizes calcium entry at the neuromuscular junction, leading to reduced acetylcholine release and muscle relaxation. In the CNS, it may act as a noncompetitive antagonist of NMDA receptors, exerting anticonvulsant effects.
Potassium chloride provides potassium ions, essential for maintaining cellular membrane potential, nerve impulse transmission, and muscle contraction. Dextrose provides a source of glucose for cellular metabolism, and sodium chloride provides sodium and chloride ions for electrolyte balance.
1 to 4 g intravenously as a 5% to 20% solution, rate not exceeding 150 mg/min; dosing frequency depends on indication (e.g., preeclampsia/eclampsia: 4-5 g IV loading then 1-2 g/hr infusion; hypomagnesemia: 1-2 g IV over 1-2 hours, may repeat based on serum magnesium levels).
Intravenous infusion. Dose based on individual electrolyte and fluid requirements, typically 500-1000 mL/hour for correction of hypokalemia; maximum infusion rate: 10 mEq potassium per hour via peripheral line, 20 mEq/hour via central line. Potassium concentration should not exceed 40 mEq/L peripherally or 80 mEq/L centrally.
None Documented
None Documented
Terminal half-life approximately 4-5 hours in normal renal function; prolonged in renal impairment (up to 40 hours).
Potassium (plasma): ~1-1.5 hours; total body potassium half-life ~10-12 hours. Clinically, steady state reached in 2-3 days with continuous infusion.
Primarily renal (90-100% as unchanged magnesium). Less than 1% biliary/fecal.
Potassium: primarily renal (90% excreted in urine); sodium: renal (90-95%); chloride: renal; dextrose: metabolized to CO2 and water. Less than 1% fecal elimination.
Category C
Category A/B
Electrolyte
Electrolyte